Here are 1-2 brief analogies to describe Research Alliance IV (RACD):

• It's like a healthcare-focused Goldman Sachs that, instead of advising on an IPO, *is* the publicly traded company that acquires a private healthcare firm to bring it to the stock market.
• Think of it as a private equity firm (like Blackstone) specialized in healthcare, whose sole mission is to acquire one private company and immediately take it public.

• Business Combination Facilitation: Research Alliance IV is a special purpose acquisition company (SPAC) formed for the specific purpose of identifying and completing a merger, acquisition, or similar business combination with a private operating company, primarily within the healthcare or healthcare-related sectors.

Research Alliance IV (RACD) is a Special Purpose Acquisition Company (SPAC) and therefore does not have major customers in the traditional sense of selling goods or services.

Matthew Hammond, PhD Chief Executive Officer and Director

Dr. Matthew Hammond serves as the Chief Executive Officer and Director of Research Alliance IV. He is a Partner on the investment team at RA Capital Management, the sponsor of Research Alliance IV. His experience includes leading RA Capital's previous SPACs, notably Research Alliance I, which merged with POINT Biopharma. POINT Biopharma was subsequently acquired by Eli Lilly, indicating his involvement with companies that have been successfully sold to acquirers. His role at RA Capital Management, a leading life sciences-focused investment firm, demonstrates a pattern of managing companies backed by private equity firms.

Adams Francis Sherman Chief Financial Officer

Adams Francis Sherman is the Chief Financial Officer of Research Alliance IV. He submitted an initial statement of beneficial ownership as an officer of the company on July 14, 2026, which established his executive role.

Henry Stusnick Chief Business Officer and Chief Operating Officer

Henry Stusnick holds the positions of Chief Business Officer and Chief Operating Officer for Research Alliance IV. He is an Analyst on the investment team at RA Capital Management. His involvement with RA Capital Management and its series of SPACs, including Research Alliance IV, suggests a pattern of managing companies backed by private equity firms.

• Inability to Complete an Initial Business Combination: As a newly organized blank check company, Research Alliance IV's sole purpose is to effect a business combination. If the company fails to identify and complete an initial business combination within the specified timeframe, it would likely be forced to liquidate and return the funds held in its trust account to its public shareholders. This is an existential risk, as the company has no operations or revenue generating activities of its own.
• Reliance on Management's Ability and Competition for Acquisition Opportunities: The company has no operating history, and its success is entirely dependent on the ability of its management team, particularly Matthew Hammond and Henry Stusnick (both associated with RA Capital Management), to identify and acquire a suitable business. The healthcare and healthcare-related industries, which Research Alliance IV intends to focus on, are highly competitive, potentially making it challenging to find attractive acquisition targets on favorable terms.
• Potential for Shareholders to Hold a Minority Interest Post-Combination: Research Alliance IV explicitly states that it may pursue a transaction in which its shareholders, immediately prior to the completion of its initial business combination, would collectively own a minority interest in the post-business combination company. This could result in significant dilution for existing shareholders and limit their influence over the combined entity's future operations and strategic decisions.

Research Alliance IV (RACD) is a blank check company, or Special Purpose Acquisition Company (SPAC), which was incorporated on April 1, 2026, and completed its initial public offering on July 14, 2026. As such, it currently has no operating business, products, or services and therefore no existing revenue streams. Its future revenue growth over the next 2-3 years will be entirely contingent upon the successful completion of an acquisition of an operating business, followed by the performance of the acquired entity.

The expected drivers of future revenue growth for Research Alliance IV over the next 2-3 years include:

1. Successful completion of an initial business combination: As a blank check company, Research Alliance IV's primary purpose is to effect a merger, share exchange, asset acquisition, or similar business combination with one or more operating businesses. The successful identification and closing of such a transaction is the foundational driver for any future revenue generation.
2. Growth of the acquired company's existing product portfolio and services: Once an initial business combination is completed, the revenue generated by the acquired operating company's current products, services, or technologies will become Research Alliance IV's revenue. The company intends to focus its search on targets within the healthcare or healthcare-related industries, specifically those in drug development and commercialization, diagnostic, and healthcare technology and service sectors.
3. Development and commercialization of new products or services by the acquired company: Given Research Alliance IV's target focus on innovation-driven healthcare sectors, the acquired entity's ability to successfully research, develop, obtain regulatory approval for, and launch new therapies, diagnostic tools, or healthcare technologies will be a significant driver of revenue expansion.
4. Expansion into new markets or increased market penetration by the acquired company: The future revenue growth will also depend on the acquired company's capacity to expand its market reach, either by entering new geographical regions or therapeutic areas, or by increasing its market share and customer base for its existing offerings within the healthcare landscape.